- Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trialBauer, Todd Michael; Felip, Enriqueta; Mok, Tony S. K.; Wu, Yi-Long; Liu, Geoffrey; Goto, Yasushi; Kim, Dong-Wan; Paolini, Jolanda; Polli, Anna; Solomon, Benjamin J.Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)Solomon, B. J.; Ahn, J. S.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J. S.; Zhong, W. Z.; Horinouchi, H.; Mao, W.; Hochmair, M. J.; De Marinis, F.; Migliorino, M. R.; Bondarenko, I.; Lohmann, T. O.; Xu, T.; Gavaldon, A. Cardona; Bordogna, W.; Ruf, T.; Wu, Y. L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 3
- Envonalkib vs crizotinib in treatment-naive advanced ALKpositive NSCLC: A randomized, multicenter, phase III trialZhang, L.; Fang, W.; Min, J.; Yang, N.; Yu, Q.; Cheng, Y.; Zhao, Y.; Li, M.; Chen, H.; Ren, S.; Zhou, J.; Zhuang, W.; Qin, X.; Cao, L.; Yu, Y.; Zhang, J.; He, J.; Feng, J.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
会议论文
Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK plus patients with (w) and without (w/ o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs)
6阅读
